dialcat: diabet acceler cognit impair alzheim disease, comprehens approach adher treatmentreto dialcat: diabet acceler cognit impair alzheim disease, comprehens approach adher treatment cristian barrue1, roger vila1, antonio b. martinez1, mario martn1,javi vazquez-salceda1 rafael simo2,4, marta barroso1, ulis cortes1,3 1 universitat politecnica catalunya, scienc department, barcelona, spain 2 vall dhebron institut recerca (vhir), barcelona, spain 3 barcelona supercomput center, barcelona, spain 4 ciberdem (instituto salud carlo iii), barcelona, spain {cbarrue, abstract. article, present design mhealth support senior citizen chronic diseas manag adher pharmacolog treatment. dialcat consist smart pill dispens mobil applic test clinic studi 18 month patient suffer diabet mild cognit impairment. clinic trial aim studi effect diabet acceler cognit impair alzheim diseas impact adher treatment. dialcat ris3cat project co-fund european erdf programme. keywords. ehealth, activ assist living, diabetes, mild cognit impairment, treatment adher- ence, mhealth. 1 introduct accord world health organis [41], 47m peopl world form dementia, effect intervention, halt revers progress cognit impairment. europ popul ageing, long-term care elderli citizen increas cost society. manag transit healthcar polici eu individu member state heavili focus extend independ life elderly, dual aim increas qualiti life (qol) reduc cost care. time exist robust epidemiolog data [35] show patient diabet mellitu type 2 (dm2) present 2-3 preval sever cognit impair alzheim diseas (ad) gener popul compar age. circumst pose sever social health problem. popul gener approxim 5,500 million euro spain healthcar system. diabet patient mild cognit im- pairment (mci) group particular predisposit develop ad gener compos polymed patients. moreover, cognit impair impli kind computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 issn 2007-9737 patients, things, lack treatment adher error drug manag consequences. treatment adher understood, measur person action - medicin intake, follow diet, and/or implement lifestyl chang - correspond health profession recommendations. undeni patient difficulti follow recommend doctor, sever compromis effect treatment creat critic problem health qol point view econom terms. dm2 patient paradigm polymed- icat patient if, also, present certain degre cognit decline, forget mis- take drug manag increas significantli [37]. provid mean facilit increas adher theoret treatment tremend social-sanitari impact. dialcat project initi fund european erdf programm propos comprehens multidisciplinari approach problem includ observ clinic research pilot intervent studi improv metabol control dm2 patient mci. object project improv treatment adher patient detect possibl advers effect aris polymedication, particular, decreas metabol control, intervent clinic trial ultim goal avoid delai possibl appear ad. dialcat propos innov element, develop valid electron drug dispens allow adher support monitoring. devic integr mhealth applic develop valid trial facilit treatment manag patient caregiv interact directli involv stakehold (clinician pharmacists) order increas concord and, consequently, effici improv metabol control. paper focu descript dialcat mhealth intervent pilot study. 1.1 plan work plan paper following, section 2 treatment adher problem, section 3 address relat work explain relev ehealth platform implement support treatment adherence. section 4 develop dialcatarchitecture, deploy goals. section 5 explain object pilot studi insight inform dialcat stakeholders. section 6 devot discuss conclus comment futur work. 2 adher chronic diseas signific grow problem population. far lead caus mortality, repres 86% death eu. adher long-term therapi chronic ill develop countri averag 50%. develop countries, rate lower. undeni patient experi difficulti follow treatment recommend [40]. individu suffer (or more) chronic diseas receiv complex polypharmaci therapy. high pill burden decreas adher drug therapy, result need larg number pill form medic regular basis. adher rate typic higher patient acut conditions, compar chronic conditions, adher drop dramat month therapi [26] prophylaxis. poor adher long-term therapi sever compromis effect treatment mak- ing critic issu popul health perspect qualiti life health economics. treatment non-adher consid signific health care problem. fact especi true patient chronic ill adher crucial factor effect therapi [6]. concord adher manag high priority, have signific effect cost-effect therapy. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 cristian barru, roger vila, antonio b. martinez, mario martn,javi vzquez salceda, rafael sim, et al.352 issn 2007-9737 especi import disord high healthcar costs, oncolog diseases, psychiatr disorders, hiv, geriatrician disord dementia. initi attempt address medicin non-adher promot patient involv treatment deci- sions, singl intervent strategi packag strategi shown effect patients, condit settings. abil patient follow treatment plan optim frequent compromis barrier, usual relat differ aspect problem. includ social econom factors, healthcar team/system, characterist diseas therapi patient-rel factor [40]. trosl defin non-adher unavoid by-product collis clinic world compet world work, play, friendship famili life [39]. intervent appli high-technolog potenti support therapi adher patient diseas requir polypharmacolog treatment. pharmacist care help reach optim cooper patients, healthcar profession high technolog interventions, main object improv rate patient adher long-term therapy. treatment non-adher expens potenti deadli problem, result 89,000 death 100 billion dollar year unnecessari hospit costs, usa. estim 194,500 death year eu miss-dos non-adher prescrib medic [27]. non-adher estim cost european union 125be annual [27]. unus medic return uk incinerated. uk 10% drug wast inciner year, valu 369.6 me. studi consist signific cost-sav increas effect health intervent attribut intervent improv adher [36]. address deter- minant adherence, advanc biomed technolog fail realis potenti reduc burden chronic illness. intervent target adher tailor particular illness-rel demand experienc patient, mainli care need chronic condit base patient self-manag (usual requir complex multi- therapies) chang lifestyle. 3 relat work despit technic advanc telehealth, sensors, cognit system social networks, system control medic non-adher integr embed care process, especi medic adher fulfil assess home. 3.1 method assess adher accur assess adher behaviour necessari effect effici treatment planning, ensur chang health outcom attribut recommend regimen. indisputably, gold standard measur adher behaviour [9]. tradit adher assess method standard clinic practic yield inaccuraci standalon method [16]. main approaches: patient caregiv self-report, review refil record pill counts. pharmacist assess question includ self-report method. 1. self-report: clinician tradition reli self-report assess medic adher treatment. visit, pa- tient/caregiv ask set direct ques- tion medic us treatment concord (e.g. diet, physic activity, etc.). time user answer posit false, avoid alien provid discomfort share difficulti associ medic use. interview method proven reliabl [10]. altern interview method obtain inform [33] consist formul open-end question like tell medications?. exampl computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 dialcat: diabet acceler cognit impair alzheim disease... 353 issn 2007-9737 self-assess valid clinic screen tool moriski scale [24]. 2. prescript refil methods: partial us assess medic adher patient purchas medic singl sourc electron recip avail allow track purchase. inform obtain like gener inadequ [11] obtain inform refilling, prescript renew provid inform real consumption. 3. pill counts: consid us method assess adherence, proven unreliable, tend overestim adher [31]. 3.2 type non-adher treatment non-adher caus vari patient broadli categoris uninten- tional intentional. unintent non-adher involv intend medic follow treatment pattern instruct fail reason (e.g. forgetfulness, carelessness). unintent non-adher influenc patient characteristics, treatment factor patient-provid issues. contrast, intent non-adher involv make reason deci- sion follow treatment instruct base perceptions, feel beliefs. intent non-adher reflect ration decision-mak process patient benefit treatment weigh advers effect treatment. broadli characteris non-adher oversimplifi complex involv non-adherence, practic illustr mitig non-adher requir differ interventions. 3.3 non-ict medic manag assess tool scale assess tool design evalu patient medic manag skills. scale cover differ aspect relat adher medic process instance: abil read understand label properly. abil open, withdraw proper medic close medic containers. abil understand medic regimen requirements. abil follow correct time food/liquid co-ingest indications. valid scale have physic depend activ daili live cognit impair independ risk factor poorer perform [16]. thorough review studi tool assess medic manag skill perform 44 differ instrument (26 invalidated, 18 validated) show skill assessed, method assessment, highli variabl [8]. valid instrument standardised, simul medic regi- men, invalid instrument patient medic inadequ instruct enabl standardis administration. conclude, said reliabl standard scale tool measur patient adher abil manag medic wide accept recommend clinic best-practis guidelines. differ measur report literature, substanti variat studi design definit report suggest need increas standardis terminolog definit measur adher persist allow comparison studi [1]. 3.4 ict aid adher assess solut exist support medic adherence; rel low technolog meth- od (e.g. pill boxes, pill counts) adher assess commonli used, newer ict tool developed. includ autom pill dispensers, refil remind intak remind telehealth approaches. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 cristian barru, roger vila, antonio b. martinez, mario martn,javi vzquez salceda, rafael sim, et al.354 issn 2007-9737 pill dispens dozen solut avail market, simpl low cost complex expensive. classifi categories: passive: passiv pill dispens includ low technolog solut pillbox enact storag role adher process. solut market, classifi medic doses, week dai eas intake. storag style help remind pill correspond intake, contribut medic adher complet unproven. reminders: remind categori lowest technolog profil pill box attach alarm clock alert user medic (medglid [17], med-q [20], med-tim [26]) smart: category, devic capac includ previou ones, extra element provid advanc services. instance, phillip medic dispens servic [28] retir miss dose left tray, provid instruct medicin resist energi failures. pillo [30], offer facial recognition, remind possibl share dispens activ famili caregiv internet. ict technolog relat adher- enc support target pharmacist like medic dispens [18] support prepar person medic blisters. [23] explor pill dispens associ multi-ag abl provid alert interact differ actors. differ solut present technolog aid design help patient adher medic schedules, current market directli patient caregivers. design patient friendli low cost, technolog aid support adequ reliabl valid data [16]. control trial compar system convent method lacking. patent search perform european patent offic engin keyword like treatment adher pill dispens author got 800 hits. patent group pill cap medicin bottl (some alarm counters), industri machin pharmaci industry, protect case pill blisters, manual devic blister pill extraction, pill count displai mechan pill dispensers. mobil app social network market, softwar solut orient mobil phones. applic provid program remind dosag configura- tion medic (pillboxi [29]), remind appoint doctor incorpor contact phone (med oclock [19]) includ complex servic health manag (myquest patient [25]). studi present dayer [5] smartphon medic adher app examin 160 adher app show app classic remind provid enhanc servic like complex treatment instructions, onlin databas provid data entry. medic adher tool reach social networks, instance, crohnolog social network gather stakehold contribut treatment crohn disease. caregiverspro-mmd [7] social network support peopl live dementia caregivers, provid treatment adher support features. work focus evalu effect medic remind young individu avail social network [21]. osteolink [15] aal fund project explor us social network connect patient care provid osteoporosi context. practic social support consist associ greater medic adher [34], studi associ greater adher us social network needed. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 dialcat: diabet acceler cognit impair alzheim disease... 355 issn 2007-9737 fig. 1. dialcat architectur eu fund project eu fund project us telehealth platform monitor specif pathologies, offer medic adher check us self-report (chroniu [3], comoesta [4], heartcycl [12], monarca [22]). project focus improv adher treatments, ict like hivind [13] project tri improv adher hiv treatment us mobil phone messag ict focus develop new best-practic medic trial (quatro [32], improvingadher [14], abc [2]). medic [38] project includ us ict base pill dispens improv adher studied, result product reach actual standard reach market. 4 dialcat mhealth platform dialcat project propos develop innov mhealth platform well-tailor personalis servic substanti improv chronic patient medic treatment adher- enc (see architectur figur 1). dialcat platform incorpor elements: i) smart pill dispens develop provid medic prescrib times, control miss dose includ sensors, control drug stock provid characterist iot device; ii) dialcat mobil app empow user abil self manag treatment obtain tailor inform feedback depend treatment concordance. dialcat offer user opportun self-manag personalis therapeut programm medic supervis home dialcat platform. lead patient achiev treatment goal(s) prefer environment, improv motivation, provid object assess personalis protocol outcom process. furthermore, provid uniqu opportun gather larg data adher therapeut regimen outcom extend period time, share computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 cristian barru, roger vila, antonio b. martinez, mario martn,javi vzquez salceda, rafael sim, et al.356 issn 2007-9737 increas knowledg user lifestyl evolution, predict potenti risk benefit avoid cold start effect new user start us dialcat platform. dialcat platform abl provid time precis indic patient adher produc relev report help clinician improv personalis treatment react necessary. 4.1 dialcat smart pill dispens dialcat s smart pill dispens set capabl differ avail market fact connect dialcat feed user adher data. dispens allow manag following: drug need provid specif time place. drug provid belong user link dispenser. inform pill remov specif cell recorded. devic design work home environ need refil weekly. drug refil servic perform train pharmacists, current common practic spanish health instance, perform train users. technolog barrier us devic low usabl kind users. design devic consid us low-cost materi afford peopl possibl reach commerci phase. main capabl devic are: reminders: devic warn user time pill in-tak day. blink light later us acoust alarm end in-tak time slot get closer. connect mhealth platform provid updat inform drug in-tak schedule; remind dynam gener depend treatment changes. 7 4 system: devic 28 pill cells, seven row weekdai slot dai standard in-tak dose (breakfast, lunch, dinner, night). devic uniqu identifi user link dialcat mhealth platform inform treatment. drug store follow european standard medic contain isolation. adher control: instal sensor base ir led technolog allow detect pill guarante precis 5mm. cell control set sensor control presenc pill (see figur 2). sensor allow dialcat dispens detect time dai user take pill devic happen. stock control: sensor box allow control moment statu device, control cell empti not. allow detect wrong in-tak (empti cell certain moment) need refil devic soon, allow alert user properli appoint servic provider. soundness: devic provid mean continu offer services, electr power avail (thank includ battery) internet connect failing. case, devic allow user retriev medication. inform stored, sent condit allow mhealth platform updated. figur 3 firmwar flux diagram normal oper dispenser. design, prototyp intern valid phases, devic actual product phase. project pilot study, 140 unit assembl time write paper. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 dialcat: diabet acceler cognit impair alzheim disease... 357 issn 2007-9737 fig. 2. ir sensor screen cell 4.2 dialcat mobil app mhealth platform allow integr inform come extern devic smart dispens (e.g. glucometer) inform gener platform interact patient connect differ actor therapeut process: patients, doctors, caregiv pharmacists. order establish communication, addit digit platform integr data collect automatically, control panel doctor caregiv developed, enabl interact inform exchang regard therapy. applic allow doctor contact patient time contact doctor patients, allow flexibl flow inform clinic real time avail today. authoris caregivers/rel connect platform inform monitor patient health, adher treatment evolut therapy. end cycle, pharmacist connect patient doctor receiv order replenish medic dispens valid treatment schedul specif patient. control panel, abl check medic load dispens patient contain dispens (e.g. suppositories, injections, syrups, etc.). contain dispenser, devic remind user them. addit platform doctors, mobil applic allow patient caregiv feedback follow-up therapi answer questionnair pharmacolog treatment, lifestyle, diet, exercise, etc. inform transpar integr platform gener statist report avail clinicians. platform allow provid remind treatment motiv messag continu adher treatment. monitor report unexpect effect (mainli drug-drug interact polymed context), analys possibl action mechan explain effect. special advers effect relat decreas metabol control particular importance. main featur dialcat digit platform are: commun channel therapeut process stakehold format chat control panel manag patient medic report adher health variabl (i.e. glycemia) adher support re- minder personalis messag questionnair collect health data patient (i.e. glycemia measures) integr servic extern devic like smart dispens glucomet us api easi intuit user experi 5 dialcat studi overal object evalu improv metabol control hypertens promot adher treatment commun patient medic equip prevent delai process cognit declin convers ad diabet patient mci. intervent computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 cristian barru, roger vila, antonio b. martinez, mario martn,javi vzquez salceda, rafael sim, et al.358 issn 2007-9737 fig. 3. dialcat main algorithm computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 dialcat: diabet acceler cognit impair alzheim disease... 359 issn 2007-9737 appli studi dialcat digit platform compos smart pill dispens mhealth platform. studi begin begin 2019. studi design: control clinic trial, prospective, randomis parallel groups. studi regist clinic trial.gov.registry. primari objective: evalu effect intervent progress cognit impair 1 elderli popul (60-79 years) dm2 mci. secondari objectives: 1. evalu intervent mention improv metabol control. 2. evalu effect intervent convers rate mci ad. 3. compar effect intervent reduc memori drop convers rate ad. 4. identifi clinic analyt predictor (biomarkers) convers mci ad. participants: patient dm2 mci (n = 174) follow 18 months. particip includ hospit center particip project (vall dhebron institut recerca, parc sanitari pere virgili, fundacio althaia, fundacio univesitaria del bages, consorci sanitari terrassa, fundacio privada hospit asil granollers, consorci hospitalari vic, fundacio docencia recerca mutua terrassa). gener clinic variabl evaluation: gener clinic variabl analyz following: age, gender, ethnicity, education, anthropometr measur (bodi mass index waist circumference), presenc cardiovascular risk factor (hypertension, dyslipidemia, smoking), alcohol consumption, 1assess memori test includ cognit batteri pharmacolog treatment famili histori dementia. relat dm2, follow variabl recorded: type time evolut diabetes, metabol control data (basal glycaemia hba1c) presenc absenc complic diabetes: retinopathy, nephropathy, neuropathi cardiovascular diseas (ischem heart disease, stroke peripher arteriopathy). inclus criteria: 1) durat diabet 5 years. 2) ag 60 75 years. 3) mci (defin criteria). exclus criteria: 1) ad antecedents. 2) patient type dementia. 3) histori neurolog psychiatr condit substanti affect cognition, produc sensori impair mobil limit prevent restrict applic evalu intervention, import health problem (for example, recent cardiovascular event clinic relevant, renal disease, oncolog treatment). randomization: patient elig dm2 randomis 1: 1: 1 ratio branches. alloc treatment base randomli gener list link singl number treatments. randomisation, sex-by-sex-swap sequenc apo genotyp used. given factor expect synergist effects, effect cumul intervent studi 3 parallel arm follow intervent applied: group a: dm2 patient (n = 58) mci receiv treatment recommend primari / endocrinologist. group b: dm2 patient (n = 58) mci apart standard treatment enjoi dialcat smart dispens allow support monitor treatment adherence. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 cristian barru, roger vila, antonio b. martinez, mario martn,javi vzquez salceda, rafael sim, et al.360 issn 2007-9737 group c: dm2 patient (n = 58) mci who, addit dispenser, receiv period feedback metabol control improv medic devic dialcat mhealth digit platform. abil possibl necessari technolog support (tablet platform) criterion exclus assign group. case, taken account level statist analysis, mainli intent treat. given expect differ factor addit synergist effect, hypothesi cognit impair progress mci ad be: group 1 > group 2 > group 3. inform consent secur monitoring: inform consent obtain subject, centr ethic committe evalu studi approval. 6 conclus futur work senior cognit impair feel great need public awar diseas support caregivers. treatment revers halt diseas progress avail dementias, forese future, treatment medic dementia remain centr entir diseas management. slow rate cognit declin earli diagnosi essenti give patient best chanc maintain cognit ability. dialcat offer potenti solv patient non-adher encourag self-manag treatment make possibl continu therapeut regimen, reduc cost patient, caregiv health system. improv treatment adher develop target intervent mhealth platform channels, crucial address specif reason patient abl will execut treatment plan. perspective, intervent messag personalis tailor address individu need beliefs. definit tailor describ featur tailor health messag differ approaches: assessment-based, result, messag individual-focused. words, tailor base gather assess person data relat health outcom determin order determin effect strategi meet personatm needs. characteristics, tailor messag provid person feedback, command greater attention, process deeply, perceiv likeabl patient gener message. possibilities, tailor health messag like gener inform read, remembered, view person relevant. technolog like smart pill dispens potenti us data gener process actor health ecosystem. moreover, integr health data collect mhealth applic standard clinic health records, provid holist view patient treatment concord support tool improv decis making. step dialcat project finalis industri product 140 smart dispens unit start clinic trial januari 2019. month data collection, consortium abl process start machin learn techniqu cluster differ type patient regard adher detect connect adher rate diseas evolution. clinic valid ict adher support propos dialcat leap ahead design kind technologies. moreover, consortium abl compar adher rate detect dialcat platform on gener typic clinic adher scale (e.g. moriski [24]) includ dialcat s clinic trial screen process. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 dialcat: diabet acceler cognit impair alzheim disease... 361 issn 2007-9737 acknowledg author partial support project dialcat: diabet acceler cognit impair alzheim disease, comprehen- sive approach adher treatment (dia) co-fund european region develop fund (erdf) european union, oper erdf catalonian framework 2014-2020. view express paper necessarili consortium cmmd. prof. cort member sistema nacion investigador (sni-iii), (conacyt, mexico). refer 1. andrade, s. e., kahler, k. h., frech, f., & chan, k. a. (2006). method evalu medic adher persist autom databases. pharmacoepidemiolog drug safety, vol. 15, no. 8, pp. 565574. 2. ascertain barrier compliance: polici safe, effect cost-effect us medicin europ (abc) (2012). factsheet/en. 3. chroniu (2012). 4. comoesta (2010). eu/project/rcn/85409/factsheet/en. 5. dayer, l., heldenbrand, s., anderson, p., gubbins, p. o., & martin, b. c. (2013). smartphon medic adher apps: potenti benefit patient providers. journal american pharmacist association, vol. 53, no. 2, pp. 172181. 6. dimatteo, m. (2004). variat patient adher- enc medic recommendations: quantit review 50 year research. medic care, vol. 42, no. 3, pp. 200209. 7. dunn, r., zafeiridi, p., wolverson, e., & paulson, k. (2016). consult end-us design usabl caregiverspro-mmd: internet base support tool design peopl dementia caregivers. alzheim europa, pp. po3.29. 8. elliott, r. a. & marriott, j. l. (2010). review instrument clinic practic assess patient abil manag medications. journal pharmaci practic research, vol. 40, no. 1, pp. 3642. 9. farmer, k. c. (1999). method measur monitor medic regimen adher clinic trial clinic practice. clinic therapeutics, vol. 21, no. 6, pp. 10741090. 10. hansen, r. a., kim, m. m., song, l., tu, w., wu, j., & murray, m. d. (2009). adherence: comparison method assess medic adher classifi nonadherence. annal pharmacotherapy, vol. 43, no. 3, pp. 413422. 11. haynes, r. b., mcdonald, h. p., garg, a., & montague, p. (2002). intervent help patient follow prescript medications. cochran databas systemat reviews, , no. 2. 12. heartcycl (2013). 13. hivind (2014). project/rcn/90123/factsheet/en. 14. improvingadher (2015). europa.eu/project/rcn/105706/factsheet/en. 15. intern osteoporosi foundat (2010). osteolink. tbreakosteolink/. 16. maclaughlin, e. j., raehl, c. l., treadway, a. k., sterling, t. l., zoller, d. p., & bond, c. a. (2005). assess medic adher elderly. drug & aging, vol. 22, no. 3, pp. 231255. 17. medglid (2018). medglider.html. 18. medic dispens (2018). medicaldispenser.cinfa.com. 19. medoclock (2012). 20. medq (2018). 21. milton s. hershei medic center (2017). us social media improv medic adher- enc adolesc young adult sys- temic lupus. show/nct03218033. 22. monarca (2013). project/rcn/93747/factsheet/en. 23. moreno, j., cortes, u., garcia-gasulla, d., gomez-sebastia, i., & alvarez-napagao, s. (2013). appli coaala spider. gibert, k., botti, v. j., & bolano, r. r., editors, proc. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 cristian barru, roger vila, antonio b. martinez, mario martn,javi vzquez salceda, rafael sim, et al.362 issn 2007-9737 16th int. conf. catalan associ artifici intelligence, volum 256 frontier artifici intellig applications, io press, pp. 326335. 24. morisky, d., green, l., levine, & d.w. (1986). concurr predict valid self-report measur medic adherence. medic care, vol. 24, pp. 6774. 25. myquest patient (2018). questdiagnostics.com. 26. nation council patient inform ed- ucat (2007). enhanc prescript medicin adherence: nation plan. nation council patient inform education. 27. pharmaceut group european union (2008). target adherence. eu/en/policy/5-adherence.html. 28. phillip (2018). autom medic dispens- ing service. pill-dispenser/health-mdp.html. 29. pillboxi (2012). 30. pillo (2018). technology/. 31. pullar, t., kumar, s., tindall, h., & feely, m. (1989). time stop count tablets? clinic pharmacolog & therapeutics, vol. 46, no. 2, pp. 163168. 32. qualiti life follow adher therapi peopl disabl schizophrenia carer (quatro) (2004). europa.eu/project/rcn/60242/factsheet/en. 33. raehl, c. l., bond, c., woods, t., patry, r. a., & sleeper, r. b. (2002). individu drug us assess elderly. pharmacotherapy: journal human pharmacolog drug therapy, vol. 22, no. 10, pp. 12391248. 34. scheurer, d., choudhry, n., swanton, k. a., matlin, o., & shrank, w. (2012). associ differ type social support medic adherence. american journal manag care, vol. 18, no. 12, pp. e4617. 35. simo, r., ciudin, a., simo-servat, o., & hernandez, c. (2017). cognit impair dementia: new emerg complic type 2 diabetesth diabetologist perspective. acta diabetologica, vol. 54, no. 5, pp. 417424. 36. simon-tuval, t., neumann, p. j., & greenberg, d. (2016). cost-effect adherence-enhanc interventions: systemat review. expert review pharmacoeconom & outcom research, vol. 16, no. 1, pp. 6784. pmid: 26732615. 37. smith, d., lovell, j., weller, c., kennedy, b., winbolt, m., young, c., & ibrahim, j. (2017). systemat review medic non-adher person dementia cognit impairment. plo one, vol. 12, no. 2, pp. 119. 38. control, identif deliveri prescrib medic (medicate) (2004). factsheet/en. 39. trostle, j. (1988). medic complianc ideology. social scienc & medicine, vol. 27, pp. 1299 1308. 40. world health organis (2003). adher long-term therapies. evid action. //www.who.int/chp/knowledge/publications/ adherence_report/en/. 41. world health organis (2016). dementia fact sheet. articl receiv 20/10/2018; accept 10/02/2019. correspond author cristian barrue. computacin y sistemas, vol. 23, no. 2, 2019, pp. 351363 doi: 10.13053/cys-23-2-3198 dialcat: diabet acceler cognit impair alzheim disease... 363 issn 2007-9737